Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
38.50
+0.44 (1.16%)
Jun 2, 2026, 3:00 PM CST
Hangzhou Biotest Biotech Market Cap
Hangzhou Biotest Biotech has a market cap or net worth of 5.63 billion as of June 2, 2026. Its market cap has increased by 38.49% in one year.
Market Cap
5.63B
Enterprise Value
4.23B
Revenue
449.50M
Ranking
n/a
PE Ratio
184.08
Stock Price
38.50
Market Cap Chart
Since September 8, 2021, Hangzhou Biotest Biotech's market cap has decreased from 8.23B to 5.63B, a decrease of -31.53%. That is a compound annual growth rate of -7.69%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 1, 2026 | 5.57B | 0.74% |
| Dec 31, 2025 | 5.53B | 60.13% |
| Dec 31, 2024 | 3.45B | 6.92% |
| Dec 29, 2023 | 3.23B | -34.48% |
| Dec 30, 2022 | 4.93B | -33.91% |
| Dec 31, 2021 | 7.46B | -9.37% |
| Sep 8, 2021 | 8.23B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Jiangsu Aidea Pharmaceutical Group | 6.30B |
| Shanghai OPM Biosciences | 6.26B |
| Chengdu Kanghua Biological Products | 6.24B |
| Wuhan Keqian Biology Co.,Ltd | 6.16B |
| Anhui Huaheng Biotechnology | 5.88B |
| Novogene | 5.87B |
| Shenzhen Weiguang Biological Products | 5.74B |
| Beijing Konruns Pharmaceutical | 5.39B |